What is INTEGRATED BIOPHARMA INC's earnings per share (EPS)?

INTEGRATED BIOPHARMA INC (INBP) reported diluted earnings per share of $0.03 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INTEGRATED BIOPHARMA INC (INBP) Financials

INBP

Trailing 12 months to March 31, 2026

Revenue $48.3M -8.8% YoY

Net Income -$1.7M -231.9% YoY

EPS (Diluted) -$0.06 -220.0% YoY

Free Cash Flow $2.8M +199.6% YoY

Market Cap $5.4M as of Sep 17, 2026

Price / Sales 0.1x on $48.3M revenue, trailing 12 months to March 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to March 31, 2026

Price / Book 0.3x on $19.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported May 8, 2026 Currency USD FYE June

Newest figures come from the 10-Q for Q3 FY2026, filed May 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INBP SEC filings page.

INTEGRATED BIOPHARMA INC (INBP) reported $48.3M in revenue over the twelve months to Mar 31, 2026, down 8.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INBP FY2025 2026-08-30

A margin recovery is the dominant mechanic: modest sales growth is now converting into cash generation.

FY2025's operating cash flow of $2.1M exceeded net income of $808K, indicating that earnings were supported by cash-producing operations rather than only accounting adjustments. With free cash flow at $1.9M, the business retained most operating cash because reinvestment needs were modest.

The 2023–25 margin shape is more than a volume story: gross margin recovered from 8.0% in FY2023 to 10.2% in FY2025, while operating margin moved from 0.2% to 3.7%. That widening points to improved cost absorption or mix, although the data cannot isolate which mechanism dominated.

The current ratio rose from 2.9x in FY2024 to 4.4x in FY2025, giving working capital more cushion. Total liabilities also declined, leaving operations less reliant on external financing; however, inventory remains a meaningful part of current assets.

Financial Health Signals

Financial health score not available

INTEGRATED BIOPHARMA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.09

INTEGRATED BIOPHARMA INC scores 2.09, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

INTEGRATED BIOPHARMA INC passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.56x

For every $1 of reported earnings, INTEGRATED BIOPHARMA INC generates $2.56 in operating cash flow ($2.1M OCF vs $808K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

43.91x

INTEGRATED BIOPHARMA INC earns $43.91 in operating income for every $1 of interest expense ($2.0M vs $46K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$10.1M

YoY-27.5%

QoQ-10.4%

5Y CAGR-10.0%

10Y CAGR-0.8%

INTEGRATED BIOPHARMA INC generated $10.1M in revenue in Q3 2026. This represents a decrease of 27.5% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.

EBITDA

-$1.0M

YoY-223.9%

QoQ-21.8%

INTEGRATED BIOPHARMA INC's EBITDA was -$1.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 223.9% from the same quarter a year earlier. Against the prior quarter it is down 21.8%.

Net Income

-$837K

YoY-237.0%

QoQ-9.8%

INTEGRATED BIOPHARMA INC reported -$837K in net income in Q3 2026. This represents a decrease of 237.0% from the same quarter a year earlier. Against the prior quarter it is down 9.8%.

EPS (Diluted)

-$0.03

YoY-250.0%

QoQ0.0%

INTEGRATED BIOPHARMA INC earned -$0.03 per diluted share (EPS) in Q3 2026. This represents a decrease of 250.0% from the same quarter a year earlier. It is unchanged from the prior quarter.

Cash & Balance Sheet

Free Cash Flow

$517K

YoY+3.4%

QoQ-12.8%

5Y CAGR-14.6%

10Y CAGR+6.5%

INTEGRATED BIOPHARMA INC generated $517K in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 3.4% from the same quarter a year earlier. Against the prior quarter it is down 12.8%.

Cash & Debt

$5.8M

YoY+96.8%

QoQ+9.6%

5Y CAGR+123.3%

10Y CAGR+29.2%

INTEGRATED BIOPHARMA INC held $5.8M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

31M

YoY+2.5%

QoQ0.0%

5Y CAGR+0.9%

10Y CAGR+3.9%

INTEGRATED BIOPHARMA INC had 31M shares outstanding in Q3 2026. This represents an increase of 2.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

-2.7%

YoY-13.8pp

QoQ-3.0pp

5Y change-18.3pp

INTEGRATED BIOPHARMA INC's gross margin was -2.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 13.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.

Operating Margin

-10.7%

YoY-16.0pp

QoQ-2.6pp

5Y change-20.8pp

INTEGRATED BIOPHARMA INC's operating margin was -10.7% in Q3 2026, reflecting core business profitability. This is down 16.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.6 percentage points.

Net Margin

-8.3%

YoY-12.7pp

QoQ-1.5pp

5Y change-15.6pp

INTEGRATED BIOPHARMA INC's net profit margin was -8.3% in Q3 2026, showing the share of revenue converted to profit. This is down 12.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.

Return on Equity

-4.4%

YoY-7.4pp

QoQ-0.6pp

5Y change-17.1pp

INTEGRATED BIOPHARMA INC's ROE was -4.4% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 7.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Capital Allocation

Capital Expenditures

YoY-100.0%

QoQ-100.0%

INTEGRATED BIOPHARMA INC reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

R&D Spending

Not reported for Q3 2026.

Share Buybacks

Not reported for Q3 2026.

INBP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INBP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1710-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$48.3M	$54.4M+8.0%	$50.3M-0.7%	$50.7M-9.9%	$56.2M-11.5%	$63.6M+20.4%	$52.8M+5.6%	$50.0M+14.3%	$43.7M-6.9%	$47.0M	$35.7M	$37.5M+11.3%	$33.7M+0.2%	$33.6M-8.1%	$36.6M-10.0%	$40.7M
Cost of Revenue	$46.0M	$48.8M+5.1%	$46.4M-0.4%	$46.6M-6.2%	$49.7M-8.1%	$54.1M+17.5%	$46.0M+5.2%	$43.8M+13.0%	$38.7M-3.9%	$40.3M	$30.7M	$33.1M+14.9%	$28.8M+2.4%	$28.1M-3.0%	$29.0M-4.9%	$30.5M
Gross Profit	$2.2M	$5.6M+43.2%	$3.9M-4.4%	$4.1M-38.0%	$6.6M-30.9%	$9.5M+40.9%	$6.7M+8.1%	$6.2M+24.7%	$5.0M-25.2%	$6.7M	$5.0M	$4.4M-10.0%	$4.9M-11.2%	$5.5M-27.7%	$7.6M-25.1%	$10.2M
SG&A Expenses	$3.5M	$3.5M-2.5%	$3.6M-7.8%	$3.9M+3.5%	$3.8M+3.0%	$3.7M+6.6%	$3.5M-1.4%	$3.5M+6.8%	$3.3M	N/A	$2.6M	$3.5M-2.0%	$3.5M-19.5%	$4.4M-46.0%	$8.1M-22.9%	$10.5M
Operating Income	-$1.2M	$2.0M+704.8%	$251K+109.2%	$120K-95.6%	$2.7M-52.5%	$5.8M+77.5%	$3.3M+20.5%	$2.7M+59.6%	$1.7M	N/A	$2.4M	$933K-31.0%	$1.4M+21.1%	$1.1M+320.6%	-$506K-39.8%	-$362K
EBITDA	N/A	$2.3M+319.0%	$558K+18.5%	$471K-84.7%	$3.1M-49.7%	$6.1M+71.4%	$3.6M+18.0%	$3.0M+48.1%	$2.0M	N/A	$2.7M	$1.3M-23.2%	$1.7M+24.0%	$1.4M+1055.8%	-$147K-1737.5%	-$8K
Interest Expense	-$36K	$46K-11.5%	$52K0.0%	$52K-59.4%	$128K-50.0%	$256K-35.5%	$397K-37.0%	$630K-32.0%	$926K	N/A	$684K	$979K+1.6%	$964K-1.5%	$979K-11.7%	$1.1M-42.8%	$1.9M
Income Tax	$536K	$1.3M+703.8%	$156K+16.4%	$134K+110.8%	-$1.2M-62.0%	-$766K+24.9%	-$1.0M-388.1%	$354K+8.6%	$326K	N/A	$265K	$134K+50.6%	$89K+423.5%	$17K+54.5%	$11K-56.0%	$25K
Net Income	-$1.7M	$808K+621.4%	$112K+429.4%	-$34K-100.9%	$3.8M-52.1%	$8.0M+95.1%	$4.1M+143.4%	$1.7M+148.6%	$679K	N/A	$810K	$735K+461.1%	$131K+40.9%	$93K+103.4%	-$2.7M-18.9%	-$2.3M
EPS (Basic)	N/A	$0.03	$0.00	$0.00-100.0%	$0.13-51.9%	$0.27+92.9%	$0.14+133.3%	$0.06+100.0%	$0.03	N/A	$0.04	$0.03+200.0%	$0.01	$0.00+100.0%	-$0.13	N/A
EPS (Diluted)	-$0.06	$0.03	$0.00	$0.00-100.0%	$0.12-52.0%	$0.25+92.3%	$0.13+116.7%	$0.06+200.0%	$0.02	N/A	$0.04	$0.02	$0.01	$0.00+100.0%	-$0.13	N/A
Diluted Shares (Avg)	N/A	31M+1.0%	31M+3.1%	30M-7.3%	32M+0.6%	32M+3.1%	31M+5.3%	30M-2.4%	30M	N/A	22M	29M	21M-0.2%	21M+1.1%	21M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$10.1M-27.5%	$11.3M-10.6%	$12.7M-6.8%	$14.2M+11.2%	$13.9M+6.1%	$12.6M+9.6%	$13.6M+5.4%	$12.7M-1.9%
Cost of Revenue	$10.4M-16.2%	$11.3M-1.7%	$11.7M-4.7%	$12.7M+10.9%	$12.4M+4.2%	$11.4M+4.1%	$12.2M+1.3%	$11.5M-4.5%
Gross Profit	-$276K-117.8%	$29K-97.5%	$1.0M-25.7%	$1.5M+14.4%	$1.6M+24.3%	$1.2M+125.2%	$1.4M+64.8%	$1.3M+30.2%
SG&A Expenses	$809K-0.4%	$943K-2.7%	$856K-2.8%	$880K-0.2%	$812K-9.1%	$969K-0.3%	$881K-0.6%	$882K-2.8%
Operating Income	-$1.1M-246.8%	-$914K-552.5%	$163K-66.7%	$589K+46.5%	$739K+108.2%	$202K+144.7%	$490K+1007.4%	$402K+408.9%
EBITDA	-$1.0M-223.9%	-$829K-390.9%	$240K-58.3%	$663K+40.8%	$815K+87.4%	$285K+176.8%	$575K+2400.0%	$471K+200.0%
Interest Expense	-$39K-680.0%	-$40K-263.6%	-$33K-135.7%	$76K+31.0%	-$5K-225.0%	-$11K-450.0%	-$14K-75.0%	$58K+61.1%
Income Tax	-$198K-218.6%	-$112K-262.3%	$73K-70.2%	$773K+429.5%	$167K+149.3%	$69K+198.6%	$245K+1784.6%	$146K+239.5%
Net Income	-$837K-237.0%	-$762K-756.9%	$123K-52.5%	-$178K-166.4%	$611K+114.4%	$116K+130.4%	$259K+539.0%	$268K+570.0%
EPS (Basic)	-$0.03-250.0%	-$0.03	$0.00-100.0%	$0.00-100.0%	$0.02+100.0%	$0.00+100.0%	$0.01	$0.01
EPS (Diluted)	-$0.03-250.0%	-$0.03	$0.00-100.0%	$0.00-100.0%	$0.02+100.0%	$0.01	$0.01	$0.01
Diluted Shares (Avg)	31M-1.4%	31M	31M+2.5%	N/A	32M+2.5%	31M	31M+2.3%	N/A

Not reported in any period shown, so not listed: R&D Expenses.

INBP Balance Sheet

INBP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1710-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$24.9M-5.0%	$26.2M0.0%	$26.2M+3.8%	$25.3M-0.7%	$25.4M+10.9%	$22.9M+15.9%	$19.8M+35.8%	$14.6M-4.1%	$15.2M	$13.6M	$11.6M+0.3%	$11.6M-8.2%	$12.6M+6.2%	$11.9M-13.0%	$13.7M
Current Assets	$18.8M+5.0%	$17.9M+9.2%	$16.4M-1.5%	$16.6M-7.6%	$18.0M+9.3%	$16.5M+16.9%	$14.1M+14.9%	$12.3M-2.3%	$12.6M	$11.6M	$9.3M+1.7%	$9.2M-7.7%	$9.9M+14.3%	$8.7M-18.3%	$10.6M
Cash & Equivalents	$3.6M+115.6%	$1.7M+27.4%	$1.3M+297.6%	$331K+57.6%	$210K-47.8%	$402K-15.4%	$475K+108.3%	$228K+72.7%	$132K	$196K	$71K-84.3%	$451K+720.0%	$55K-62.1%	$145K-80.0%	$725K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$9.4M-16.7%	$11.2M+9.6%	$10.3M-7.2%	$11.1M-5.5%	$11.7M0.0%	$11.7M+32.6%	$8.8M+13.9%	$7.7M+1.3%	$7.6M	$7.9M	$5.8M+1.4%	$5.7M-11.4%	$6.4M+21.6%	$5.3M-28.5%	$7.4M
Accounts Receivable	$5.4M+16.3%	$4.7M+3.5%	$4.5M-7.7%	$4.9M-15.4%	$5.8M+4.9%	$5.5M+24.1%	$4.4M+16.9%	$3.8M-5.6%	$4.0M	$2.7M	$2.6M+21.1%	$2.2M-9.9%	$2.4M+18.9%	$2.0M+44.8%	$1.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$4.6M-34.2%	$7.0M+6.1%	$6.6M-1.6%	$6.7M-39.9%	$11.1M-34.2%	$16.9M-5.7%	$17.9M-9.6%	$19.8M-6.3%	$21.1M	$21.1M	$20.9M-3.7%	$21.7M-5.1%	$22.9M+2.9%	$22.3M+4.3%	$21.3M
Current Liabilities	$4.2M-30.6%	$6.1M+26.8%	$4.8M-8.3%	$5.3M-43.0%	$9.2M-29.5%	$13.1M+6.0%	$12.4M-23.7%	$16.2M+45.0%	$11.2M	$10.5M	$11.9M+1.8%	$11.7M-6.1%	$12.4M+1.7%	$12.2M-42.8%	$21.3M
Non-Current Liabilities	$336K-60.3%	$846K-51.4%	$1.7M+23.4%	$1.4M-24.5%	$1.9M-50.5%	$3.8M-31.9%	$5.5M+53.0%	$3.6M-63.7%	$10.0M	$10.6M	$9.1M-10.0%	$10.1M-3.8%	$10.5M+4.3%	$10.1M+62756.3%	$16K
Long-Term Debt	N/A	N/A	$7K-86.8%	$53K	$0-100.0%	$1.4M-47.2%	$2.7M-24.9%	$3.6M-14.6%	$4.2M	$4.6M	$3.9M-9.6%	$4.4M-10.8%	$4.9M+4.0%	$4.7M	N/A
Total Equity	$20.3M+5.6%	$19.2M+2.0%	$18.9M+1.5%	$18.6M+29.6%	$14.3M+136.3%	$6.1M+220.5%	$1.9M+136.2%	-$5.2M+11.7%	-$5.9M	-$7.5M	-$9.3M+8.3%	-$10.2M+1.3%	-$10.3M+0.9%	-$10.4M-34.9%	-$7.7M
Retained Earnings	-$31.4M+2.5%	-$32.2M+0.3%	-$32.3M-0.1%	-$32.3M+10.6%	-$36.1M+18.1%	-$44.2M+8.5%	-$48.3M+3.4%	-$50.0M+1.3%	-$50.6M	-$52.2M	-$53.9M+1.3%	-$54.7M+0.2%	-$54.8M+0.2%	-$54.9M-5.2%	-$52.2M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$26.7M+3.9%	$23.5M-8.2%	$25.5M-2.5%	$24.9M-5.0%	$25.7M-4.8%	$25.7M-0.2%	$26.2M-1.7%	$26.2M0.0%
Current Assets	$18.0M-3.1%	$17.8M-1.8%	$19.6M+7.2%	$18.8M+5.0%	$18.5M+1.6%	$18.2M+6.4%	$18.3M+3.1%	$17.9M+9.2%
Cash & Equivalents	$5.8M+96.8%	$5.3M+115.9%	$4.7M+108.4%	$3.6M+115.6%	$3.0M+46.6%	$2.5M+236.2%	$2.3M-12.5%	$1.7M+27.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$8.1M-19.4%	$8.4M-24.4%	$10.5M-6.7%	$9.4M-16.7%	$10.1M-9.8%	$11.1M-8.9%	$11.2M+6.8%	$11.2M+9.6%
Accounts Receivable	$3.7M-28.1%	$3.6M-15.0%	$4.0M-9.2%	$5.4M+16.3%	$5.1M+7.6%	$4.2M+13.3%	$4.4M+5.1%	$4.7M+3.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.7M+45.8%	$3.8M-85.3%	$5.1M-23.9%	$4.6M-34.2%	$5.3M-34.3%	$25.6M+258.4%	$6.6M-14.5%	$7.0M+6.1%
Current Liabilities	$5.5M+11.0%	$3.5M-36.5%	$4.8M-21.0%	$4.2M-30.6%	$5.0M-28.3%	$5.6M-4.4%	$6.0M-2.7%	$6.1M+26.8%
Non-Current Liabilities	$2.2M+639.7%	$237K-98.8%	$287K-52.5%	$336K-60.3%	$292K-73.1%	$20.1M+1417.9%	$604K-61.3%	$846K-51.4%
Total Equity	$19.0M-6.9%	$19.8M+100112.9%	$20.5M+10.5%	$20.3M+5.6%	$20.4M+7.8%	$20K-99.9%	$18.6M-1.8%	$19.2M+2.0%
Retained Earnings	-$32.9M-5.3%	-$32.1M-0.6%	-$31.3M+2.1%	-$31.4M+2.5%	-$31.2M+3.9%	-$31.9M+2.8%	-$32.0M+1.3%	-$32.2M+0.3%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

INBP Cash Flow Statement

INBP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1710-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$3.0M	$2.1M+119.0%	$943K-23.5%	$1.2M-69.9%	$4.1M+34.1%	$3.0M+127.8%	$1.3M+308.2%	$328K-71.9%	$1.2M+194.2%	$397K	-$594K	-$113K-106.0%	$1.9M+230.5%	-$1.4M-86.5%	-$771K-296.7%	$392K
Depreciation & Amortization	N/A	$318K+3.6%	$307K-12.5%	$351K+4.5%	$336K-0.3%	$337K+8.0%	$312K-2.8%	$321K-7.8%	$348K-11.5%	$393K	$351K	$405K+3.8%	$390K+34.9%	$289K-19.5%	$359K+1.4%	$354K
Stock-Based Compensation	N/A	$185K-26.6%	$252K-21.3%	$320K-13.3%	$369K+59.7%	$231K+291.5%	$59K-59.0%	$144K+928.6%	$14K-71.4%	$49K	$31K	$104K	$0	$0-100.0%	$11K-95.7%	$255K
Capital Expenditures	$187K	$191K-65.5%	$553K+376.7%	$116K-76.1%	$486K+64.7%	$295K+37.9%	$214K-48.3%	$414K+67.6%	$247K-24.5%	$327K	$109K	$235K+29.1%	$182K+506.7%	$30K-80.6%	$155K-48.5%	$301K
Free Cash Flow	$2.8M	$1.9M+380.5%	$390K-65.1%	$1.1M-69.0%	$3.6M+30.9%	$2.8M+144.9%	$1.1M+1408.1%	-$86K-109.3%	$921K+1215.7%	$70K	-$703K	-$348K-120.5%	$1.7M+215.5%	-$1.5M-58.5%	-$926K-1117.6%	$91K
Investing Cash Flow	-$195K	-$205K+62.9%	-$553K-398.2%	-$111K+76.1%	-$465K-133.7%	-$199K-80.9%	-$110K+73.9%	-$422K-74.4%	-$242K+26.0%	-$327K	-$107K	-$156K+14.3%	-$182K-1554.5%	-$11K+92.3%	-$143K+46.8%	-$269K
Financing Cash Flow	$34K	$78K+369.0%	-$29K+78.7%	-$136K+96.1%	-$3.5M-15.2%	-$3.0M-133.7%	-$1.3M-481.8%	$341K+141.1%	-$830K-149.2%	-$333K	$1.0M	-$111K+91.5%	-$1.3M-195.6%	$1.4M+306.9%	$334K+842.2%	-$45K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	$517K-16.1%	$617K+207.0%	$1.3M+98.0%	$591K+417.7%	$616K-62.5%	$201K+111.0%	$657K-50.0%	-$186K+84.3%
Depreciation & Amortization	$75K-1.3%	$85K+2.4%	$77K-9.4%	$71K-5.3%	$76K-5.0%	$83K+2.5%	$85K+10.4%	$75K-10.7%
Stock-Based Compensation	N/A	N/A	$49K-7.5%	N/A	N/A	N/A	$53K-25.4%	N/A
Capital Expenditures	$0-100.0%	$24K-17.2%	$173K+208.9%	-$10K-93.2%	$116K-66.4%	$29K+20.8%	$56K+47.4%	$146K+711.1%
Free Cash Flow	$517K+3.4%	$593K+244.8%	$1.1M+87.7%	$581K+275.0%	$500K-61.5%	$172K+109.3%	$601K-52.9%	-$332K+72.4%
Investing Cash Flow	$6K+105.2%	-$24K+17.2%	-$173K-208.9%	-$4K+97.3%	-$116K+66.4%	-$29K-20.8%	-$56K-47.4%	-$146K-758.8%
Financing Cash Flow	-$11K	-$11K-161.1%	-$11K-57.1%	$67K+709.1%	$0+100.0%	$18K+263.6%	-$7K-333.3%	-$11K-10.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

INBP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INBP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1710-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	10.2%+2.5pp	7.7%-0.3pp	8.0%-3.6pp	11.7%-3.3pp	14.9%+2.2pp	12.8%+0.3pp	12.4%+1.0pp	11.4%-2.8pp	14.2%	13.9%	11.7%-2.8pp	14.5%-1.9pp	16.4%-4.4pp	20.8%-4.2pp	25.0%
Operating Margin	3.7%+3.2pp	0.5%+0.3pp	0.2%-4.6pp	4.9%-4.2pp	9.1%+2.9pp	6.2%+0.8pp	5.4%+1.5pp	3.9%	N/A	6.6%	2.5%-1.5pp	4.0%+0.7pp	3.3%+4.7pp	-1.4%-0.5pp	-0.9%
Net Margin	1.5%+1.3pp	0.2%+0.3pp	-0.1%-6.9pp	6.8%-5.8pp	12.6%+4.8pp	7.8%+4.4pp	3.4%+1.8pp	1.6%	N/A	2.3%	2.0%+1.6pp	0.4%+0.1pp	0.3%+7.7pp	-7.4%-1.8pp	-5.6%
Return on Equity	4.0%+3.4pp	0.6%+0.8pp	-0.2%-20.8pp	20.7%-35.2pp	55.9%-11.8pp	67.7%-21.5pp	89.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	3.2%+2.8pp	0.4%+0.6pp	-0.1%-15.3pp	15.2%-16.3pp	31.5%+13.6pp	17.9%+9.4pp	8.5%+3.9pp	4.7%	N/A	5.9%	6.3%+5.2pp	1.1%+0.4pp	0.7%+23.6pp	-22.8%-6.1pp	-16.7%
Current Ratio	4.42+1.5x	2.92-0.5x	3.39+0.2x	3.16+1.2x	1.95+0.7x	1.26+0.1x	1.14+0.4x	0.76-0.4x	1.13	1.10	0.790.0x	0.790.0x	0.80+0.1x	0.71+0.2x	0.50
Debt-to-Equity	0.23-0.1x	0.36+0.4x	0.000.0x	0.000.0x	0.00-0.2x	0.24-1.2x	1.44	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	2.18+0.3x	1.920.0x	1.93-0.3x	2.23-0.3x	2.50+0.2x	2.30-0.2x	2.53-0.5x	3.00-0.1x	3.09	2.62	3.23+0.3x	2.91+0.2x	2.67-0.4x	3.08+0.1x	2.98
FCF Margin	3.5%+2.7pp	0.8%-1.4pp	2.2%-4.2pp	6.4%+2.1pp	4.3%+2.2pp	2.1%+2.3pp	-0.2%-2.3pp	2.1%+2.0pp	0.1%	-2.0%	-0.9%-6.0pp	5.0%+9.4pp	-4.4%-1.8pp	-2.5%-2.8pp	0.2%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	-2.7%-13.8pp	0.3%-9.0pp	8.0%-2.0pp	10.4%+0.3pp	11.1%+1.6pp	9.3%+4.8pp	10.1%+3.6pp	10.1%+2.5pp
Operating Margin	-10.7%-16.0pp	-8.1%-9.7pp	1.3%-2.3pp	4.2%+1.0pp	5.3%+2.6pp	1.6%+5.5pp	3.6%+4.0pp	3.1%+2.5pp
Net Margin	-8.3%-12.7pp	-6.8%-7.7pp	1.0%-0.9pp	-1.3%-3.4pp	4.4%+2.2pp	0.9%+4.2pp	1.9%+2.4pp	2.1%+1.8pp
Return on Equity	-4.4%-7.4pp	-3.9%-591.9pp	0.6%-0.8pp	-0.9%-2.3pp	3.0%+1.5pp	588.0%+590.1pp	1.4%+1.7pp	1.4%+1.2pp
Return on Assets	-3.1%-5.5pp	-3.2%-3.7pp	0.5%-0.5pp	-0.7%-1.7pp	2.4%+1.3pp	0.4%+1.9pp	1.0%+1.2pp	1.0%+0.9pp
Current Ratio	3.25-0.5x	5.03+1.8x	4.12+1.1x	4.42+1.5x	3.72+1.1x	3.26+0.3x	3.04+0.2x	2.92-0.5x
Debt-to-Equity	0.41+0.1x	0.19-1299.6x	0.25-0.1x	0.23-0.1x	0.26+0.3x	1299.81+1299.4x	0.36-0.1x	0.36+0.4x
Asset Turnover	0.38-0.2x	0.480.0x	0.500.0x	0.57+0.1x	0.54+0.1x	0.490.0x	0.520.0x	0.490.0x
FCF Margin	5.1%+1.5pp	5.3%+3.9pp	8.9%+4.5pp	4.1%+6.7pp	3.6%-6.3pp	1.4%+17.4pp	4.4%-5.5pp	-2.6%+6.7pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
INTEGRATED BIOPHARMA INC INBP	FY2025	$54.4M	$808K	1.5%	$5.4M	—
BAB INC BABB	FY2025	$3.4M	$559K	16.3%	$6.2M	—
STEAKHOLDER FOODS LTD MTTCF	FY2025	N/A	-$11.2M	N/A	$14.7M	—

Where INTEGRATED BIOPHARMA INC Ranks

Frequently Asked Questions

What is INTEGRATED BIOPHARMA INC's annual revenue?

INTEGRATED BIOPHARMA INC (INBP) reported $54.4M in total revenue for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is INTEGRATED BIOPHARMA INC's revenue growing?

INTEGRATED BIOPHARMA INC (INBP) revenue grew by 8.0% year-over-year, from $50.3M to $54.4M in fiscal year 2025.

Is INTEGRATED BIOPHARMA INC profitable?

Yes, INTEGRATED BIOPHARMA INC (INBP) reported a net income of $808K in fiscal year 2025, with a net profit margin of 1.5%.

What is INTEGRATED BIOPHARMA INC's EBITDA?

INTEGRATED BIOPHARMA INC (INBP) had EBITDA of $2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is INTEGRATED BIOPHARMA INC's gross margin?

INTEGRATED BIOPHARMA INC (INBP) had a gross margin of 10.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is INTEGRATED BIOPHARMA INC's operating margin?

INTEGRATED BIOPHARMA INC (INBP) had an operating margin of 3.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is INTEGRATED BIOPHARMA INC's net profit margin?

INTEGRATED BIOPHARMA INC (INBP) had a net profit margin of 1.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is INTEGRATED BIOPHARMA INC's return on equity (ROE)?

INTEGRATED BIOPHARMA INC (INBP) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is INTEGRATED BIOPHARMA INC's free cash flow?

INTEGRATED BIOPHARMA INC (INBP) generated $1.9M in free cash flow during fiscal year 2025. This represents a 380.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is INTEGRATED BIOPHARMA INC's operating cash flow?

INTEGRATED BIOPHARMA INC (INBP) generated $2.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are INTEGRATED BIOPHARMA INC's total assets?

INTEGRATED BIOPHARMA INC (INBP) had $24.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are INTEGRATED BIOPHARMA INC's capital expenditures?

INTEGRATED BIOPHARMA INC (INBP) invested $191K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does INTEGRATED BIOPHARMA INC have outstanding?

INTEGRATED BIOPHARMA INC (INBP) had 31M shares outstanding as of fiscal year 2025.

What is INTEGRATED BIOPHARMA INC's current ratio?

INTEGRATED BIOPHARMA INC (INBP) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.

What is INTEGRATED BIOPHARMA INC's debt-to-equity ratio?

INTEGRATED BIOPHARMA INC (INBP) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is INTEGRATED BIOPHARMA INC's return on assets (ROA)?

INTEGRATED BIOPHARMA INC (INBP) had a return on assets of 3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is INTEGRATED BIOPHARMA INC's P/E ratio?

INTEGRATED BIOPHARMA INC (INBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $5.4M as of Sep 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is INTEGRATED BIOPHARMA INC's price-to-sales ratio?

INTEGRATED BIOPHARMA INC (INBP) trades at 0.1x sales, its market capitalization divided by revenue of $48.3M revenue, trailing 12 months to March 31, 2026. The market capitalization is $5.4M as of Sep 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is INTEGRATED BIOPHARMA INC's Altman Z-Score?

INTEGRATED BIOPHARMA INC (INBP) has an Altman Z-Score of 2.09, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is INTEGRATED BIOPHARMA INC's Piotroski F-Score?

INTEGRATED BIOPHARMA INC (INBP) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are INTEGRATED BIOPHARMA INC's earnings high quality?

INTEGRATED BIOPHARMA INC (INBP) has an earnings quality ratio of 2.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can INTEGRATED BIOPHARMA INC cover its interest payments?

INTEGRATED BIOPHARMA INC (INBP) has an interest coverage ratio of 43.91x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.